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Hypertensive complications are the most common clinical problems encountered during pregnancy.1 Hypertension 
during pregnancy encompasses many pathologies including pre-
eclampsia, pregnancy-induced hypertension, and chronic hyper-
tension. Specifically, chronic hypertension during pregnancy 
poses an increasing clinical problem.2 Pregnant women with 
chronic hypertension are at an increased risk of maternal and fetal 
morbidity and mortality, as well as a higher incidence of develop-
ing superimposed preeclampsia.3 The kidneys play a central role 
in blood pressure regulation in pregnancy. Women with chronic 
kidney disease are at increased risk of developing pregnancy 
complications, where up to 70% experience preterm delivery and 
up to 40% will develop preeclampsia.4,5 Significant structural and 
functional changes occur in the kidney during pregnancy includ-
ing a 1- to 1.5-cm increase in size, a 50% increase in glomerular 
filtration rate, and up to an 80% increase in renal plasma flow.6,7 
These alterations are broadly conserved in rats.8
The mechanisms that affect pregnancy-related changes 
in the kidney in normotensive and hypertensive women are 
incompletely understood. Unbiased screening approaches 
may have the ability to identify novel pathophysiological 
pathways. The urinary peptidome provides information about 
proteins that are involved in local processes in the kidneys and 
information about other organs obtained through filtration of 
the dynamic plasma peptidome.9 Peptides derived from pro-
cesses in the kidney and urogenital tract form the majority of 
those detected in the urinary peptidome (70%), whereas pep-
tides from the circulation constitute the remainder.10 The small 
peptides present are generally soluble and because of their 
size do not require protein digestion before analysis by mass 
spectrometry.10 Urinary peptidomics has been applied in the 
field of cardiovascular research to develop biomarker panels 
for diagnosis, prediction of disease, and risk stratification.11 In 
particular, many studies have shown that there are alterations 
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in the urinary peptidome in people with hypertension12 and in 
healthy pregnant women compared with those who develop 
preeclampsia.13
The stroke-prone spontaneously hypertensive rat (SHRSP), 
obtained by selective inbreeding of the Wistar–Kyoto (WKY) 
strain, is a well-characterized model of human cardiovascular 
disease and of maternal chronic hypertension.14 We hypoth-
esized that the urinary peptidome would be altered in both 
a pregnancy-dependent and strain-dependent manner between 
the SHRSP and control WKY strain.
Methods
Animals
Animals (WKY and SHRSP rats) were housed under controlled light-
ing (from 0700–1900 hours) and temperature (21±3°C) and received 
a normal diet (rat and mouse no. 1 maintenance diet; Special Diet 
Services, Grangemouth, United Kingdom) provided ad libitum. All 
animal procedures were approved by the Home Office according to 
regulations regarding experiments with animals in the United Kingdom 
(Project License Number 60/4286). Females were time mated at 12 
weeks of age (±4 days). Nonpregnant animals were age matched at 15 
weeks±4 days (ie, 12 weeks of age plus 21 days of pregnancy). Day 0 
of pregnancy was defined as the day that a coital plug was observed 
indicative of successful mating having taken place. A subset of SHRSP 
began nifedipine treatment at 7 weeks of age at 25 mg/kg per day 
administered in 2 doses: a 10-mg/kg per day dose mixed in a 1-mL 
aliquot of baby food and a 15-mg/kg per day dose in drinking water to 
maintain lowered blood pressure throughout the 24-hour period. Stock 
solutions of nifedipine in drinking water were prepared in ethanol and 
diluted to the appropriate concentration with no more than a 0.8% final 
ethanol concentration. The number of rats and particular gestational 
day (GD) is given in the relevant figure legend.
Metabolic Cage
The metabolic cage allows individual housing of an animal to col-
lect information on water intake and urine output over 24 hours. A 
fixed amount of water (200 mL) was given, and food was available 
ad libitum over the 24-hour period. Animals were acclimatized for 4 
hours, 3 days before measurement. For untreated WKY and SHRSP, 
urine samples were collected from virgin animals that were housed in 
the metabolic cage 1 day before mating and then at GD12 and GD18. 
For nifedipine-treated SHRSP, urine samples were collected at GD12 
and GD18. Urine samples were aliquoted on the ice and stored at 
−80°C until use.
Urinary Peptidomics
Seven hundred microliters of urine was diluted with 700 µL of 2 M 
urea and 0.1 M NH4OH containing 0.02% SDS. A size cutoff for pep-
tides <20 kDa was performed using Centrisart ultracentrifugation filter 
devices (Sartorius, Göttingen, Germany) at 3000g for 1 hour at 4°C. To 
remove urea, electrolytes, and salts, the filtrate was then ran through 
a PD-10 desalting column (Amersham Bioscience, Buckinghamshire, 
United Kingdom) and peptide elution was done using 0.01% aque-
ous NH4OH. Finally, all samples were lyophilized, stored at 4°C, and 
resuspended in high-performance liquid chromatography grade H2O 
to a final concentration of 2 µg/µL before analysis.
CE-TOF-MS (capillary electrophoresis–time of flight–mass spec-
trometry) analysis was performed using a P/ACE MDQ CE system 
(Beckman Coulter, Fullerton,) online coupled to a micro-TOF MS 
(Bruker Daltonic, Bremen, Germany) as described in the study by 
Albalat et al.15 Samples were injected with 2 psi for 99 seconds (250 
nL), and separation of peptides in the cartridge maintained at 25°C 
was attained at 25 kV for 30 minutes and increasing pressure (0.5 
psi) for another 35 minutes. The sheath liquid consisted of 30% iso-
propanol, 0.4% formic acid in high-performance liquid chromatogra-
phy grade water, and running buffer consisted of 79:20:1 (v/v) water, 
acetonitrile, and formic acid. The electrospray ionization sprayer 
(Agilent Technologies, CA) was grounded, and the ion spray infer-
ence potential was set at −4.5 kV. Spectra were accumulated over a 
mass:charge ratio of 350:3000 for every 3 seconds.
Peak picking, deconvolution, and deisotoping of mass spectral 
ion peaks were processed using Mosaiques Visu software.16 The 
CE-migration time, molecular weight, and ion signal intensity 
were normalized based on the reference signal from internal pep-
tide standards/calibrants (peptides from housekeeping proteins) in 
rats.17 For calibration, a local and linear regression algorithm was 
applied with calibrants. The peak list generated for each peptide 
consisted of molecular weight (kDa), normalized CE migration 
time (minutes), and normalized signal intensity. The peptide list 
from all the samples that passed the quality control criteria was 
compared and annotated in a Microsoft SQL database. The criteria 
for clustering peptides in different samples were as follows: (1) 
molecular weight deviation less than ±50 ppm for small peptide 
(<800 Da) and gradually increasing to ±75 ppm for larger peptides 
(20 kDa), (2) CE-migration time deviation with linear increase 
from ±0.4 to ±2.5 minutes in the range from 19 to 50 minutes. 
Each peptide was given a unique identification number (Peptide 
ID). Peptides detected with the frequency of ≥70% in at least 1 
group were considered for further analysis.
Liquid Chromatography–Tandem Mass 
Spectrometry for Peptide Sequencing
The peptide mixtures extracted for CE-MS were also used for 
sequencing of the peptides in liquid chromatography–tandem 
mass spectrometry and CE-MS/MS. liquid chromatography– 
tandem mass spectrometry sequencing was performed on an 
UltiMate 3000 nanoflow system (Dionex/LC Packings) connected 
to a linear trap quadrupole Orbitrap hybrid mass spectrometer 
(Thermo Fisher Scientific, Germany) equipped with a nanoelec-
trospray ion source. After loading (5 µL) onto a Dionex 0.1×20 
mm 5-µm C18 nanotrap column at a flowrate of 5 µL/min in 98% 
of 0.1% formic acid and 2% acetonitrile, sample was eluted onto 
an Acclaim PepMap C18 nanocolumn 75 µm × 50 cm, 2 µm 100 
Å at a flow rate of 0.3 µL/min. The trap and nanoflow column 
were maintained at 35°C. The samples were eluted with a gradient 
of solvent A: 98% water, 0.1% formic acid, and 2% acetonitrile 
versus solvent B: 80% acetonitrile, 20% water, 0.1% formic acid 
starting at 1% B for 5 minutes rising to 20% B after 90 minutes and 
finally to 40% B after 120 minutes. The column was then washed 
and re-equilibrated before the next injection. Alternatively, sam-
ples were injected and separated using a P/ACE MDQ capillary 
electrophoresis system (Beckman Coulter, Fullerton) as described 
above for CE-MS.
The eluent from the LC or CE was ionized using a Proxeon nano-
spray electrospray ionization source operating in positive ion mode 
into an Orbitrap Velos FTMS (Thermo Finnigan, Bremen, Germany). 
Ionization voltage was 2.6 kV, and the capillary temperature was 
250°C. The mass spectrometer was operated in MS/MS mode scan-
ning from 380 to 1600 amu. In LC, the top 20 multiply charged ions 
were selected from each scan for MS/MS analysis using HCD at 
40% collision energy. The resolution of ions in MS1 was 60 000 and 
7500 for HCD MS2. In CE, the top 5 multiply charged ions were se-
lected for MS/MS using a data-dependent decision tree method18 and 
fragmented by either HCD at 40% or electron-transfer dissociation, 
depending on their mass and charge state.
MS and MS/MS data files were searched, in this case, against 
the Uniprot rat nonredundant database using SEQUEST (Thermo 
Proteome Discoverer) with the nonspecific enzyme as enzyme speci-
ficity. Peptide data were extracted using high peptide confidence and 
top 1 peptide rank filters. A peptide mass tolerance of ±10 ppm and a 
fragment mass tolerance of ±0.05 Da.
Quantitative Polymerase Chain Reaction for 
Uromodulin Expression
Gene expression assay for uromodulin (Umod) in kidney tissues was 
performed using the following probes from Thermo Fisher, Paisley, 
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United Kingdom: Umod (Rn01507237_m1) and Actb (4352340E). Ct 
values were analyzed using the 2(-ΔΔCt) method, with ΔCt indicating 
normalization to the housekeeper β-actin (Actb).
Western Blot for Umod
Multistrip blotting was performed as described previously.19 Primary 
and secondary antibodies were used as per manufacturer’s instruc-
tions. Primary antibody Umod (AF5175; R&D Systems, Abingdon, 
United Kingdom) followed by secondary antibody anti-sheep horse-
radish peroxidase conjugate (HAF016; R&D Systems).
N-Deglycosylation of Umod
Umod was N-deglycosylated by PNGase F (New England Biolabs, 
Beverly, MA) under reducing conditions. 2 µg of Umod was dena-
tured with buffer provided by the manufacture and then incubated 
with PNGase F at 37°C for 1 hour. Protein samples were separated on 
reducing 4% to 12% NuPAGE gel and later blotted onto polyvinyli-
dene fluoride membrane for Umod detection.
Purification of Umod and Polymerization Assay
Urine samples from untreated WKY (n=7), SHRSP (n=7), and 
nifedipine-treated SHRSP (n=3) at prepregnancy, GD12, and 
GD18 were pooled separately. For purification, 500 µL of urine 
was filtered using a 3000 Da molecular weight cutoff column 
(Millipore). Polymerization assay was performed as described pre-
viously by Jovine et al.20 Pellet and supernatant were solubilized in 
SDS-gel loading buffer and separated on a reducing 10% NuPAGE 
gel and blotted onto polyvinylidene fluoride membrane for Umod 
detection.
Protease Prediction
To find the protease that cleaved Umod protein in vivo, Proteasix soft-
ware was used to perform in silico protease mapping as described in 
the study by Klein et al.21
Statistical Analysis
In urinary peptidomics, peptides were considered significant accord-
ing to Wilcoxon rank-sum test (P<0.05) followed by adjustment for 
multiple testing (Benjamini and Hochberg). Later repeated-measure 
ANOVA was used to evaluate significant peptides within different 
GDs. Western blot analysis was performed in LI-COR Image Studio 
software, and band intensities were made consistent with local back-
ground subtraction. Furthermore, t test, 1-way, or 2-way ANOVA test 
were used for statistical significance (P<0.05).
Results
Urinary Peptidome Is Altered During Pregnancy 
and Between WKY and SHRSP
A peptidome screen was performed in WKY and SHRSP 
urine at prepregnancy, GD12, and GD18 to identify strain, 
pregnancy, and disease-dependent alterations (Figure 1). 
The peptidomic data were subject to several comparisons 
between WKY and SHRSP at different GDs, such as (1) 
comparison within rat models at all time points and (2) 
comparison between WKY and SHRSP at a given GD. The 
longitudinal comparison (1) within the WKY and SHRSP 
resulted in the identification of 630 and 739 significant dif-
ferentially regulated peptides, respectively. These were con-
sidered to be strain- and pregnancy-dependent alterations. 
Although the comparison between WKY and SHRSP (2) 
resulted in 788 significant peptides that were considered to 
be hypertension-dependent alterations. These disease-spe-
cific peptide markers were further evaluated using repeated-
measures ANOVA. Some peptides were significantly altered 
at all time points, or at any two or at a single GD. The pep-
tides that showed significance at all time points and at both 
GD12 and GD18 were considered for further analysis. These 
123 peptides were investigated for their regulation pattern 
with cutoff criteria of ≥1.5-fold change and P≤0.05 (Table 
S1 in the online-only Data Supplement). Compared with 
WKY, urine from SHRSP consisted of 7 and 39 peptides up- 
and downregulated, respectively, at prepregnancy, GD12, 
and GD18. In addition, 36 peptides were upregulated and 41 
peptides were downregulated in SHRSP at both GD12 and 
GD18. Sequencing of these differentially expressed peptides 
revealed that they belonged to collagen α-chains, albumin, 
prothrombin, actin, serpin A3K, proepidermal growth factor, 
and Umod (Table S2).
Umod Expression Is Increased in the Urine and 
Kidney of SHRSP During Pregnancy
The CE-MS data indicated that Umod peptide expression was 
greater in SHRSP urine samples relative to WKY with a fold 
change of 4 (P<0.05) and 8 (P<0.01) at GD12 and GD18, 
respectively (Figure 2A and B). These data were validated 
in individual urine samples from WKY and SHRSP at pre-
pregnancy, GD12, and GD18 with Western blot where urine 
from SHRSP showed an increase in Umod protein expres-
sion at GD12 and GD18 with a fold change of 2.3 (P<0.05; 
Figure 3A).
Gene expression of Umod was measured in kidney tissue 
taken from nonpregnant and GD18 WKY and SHRSP. Umod 
gene expression was greater in kidney tissue from SHRSP 
both in nonpregnant and GD18 samples, but the difference 
only reached statistical significance at GD18 (P<0.001; 
Figure 3B). This finding was validated at the protein level, 
which showed greater levels of Umod in kidney tissue from 
GD18 SHRSP (Figure 3C).
C-Terminal Umod Peptides Found to Be More 
Abundant at GD12 and GD18 in SHRSP Urine
CE-MS analysis identified 7 peptides of Umod pres-
ent in the urine samples from WKY and SHRSP. Further 
sequencing of these peptides using liquid chromatography-
tandem mass spectrometry revealed that they were exclu-
sively derived from the same C-terminal region (592–609; 
Figure 4A). This region of Umod remains membrane bound 
after the formation of extracellular polymerization-compe-
tent Umod and is also known to have an inhibitory role 
in Umod polymerization. Expression of these peptides was 
significantly greater at GD12, GD18, or both in SHRSP rel-
ative to WKY. When compared with our group’s previous 
study that examined urinary peptidomics in women with 
preeclampsia, we found the ortholog peptides of Umod 
upregulated in preeclampsia.22 In another independent 
study by Kononikhin et al23 that examined the urinary pep-
tidome in mild and severe preeclampsia, the same sequence 
of peptides of Umod was identified as early predictors of 
preeclampsia (Figure 4A). The presence of these peptides 
in urine suggests that either they are cleaved by certain 
proteases from the membrane after the formation of extra-
cellular polymerization-competent Umod or from a longer 
form of Umod that retains this region. We hypothesized 
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that 2 forms of Umod exist in the urine of the pregnant rat: 
a shorter polymerization-competent and a longer polymer-
ization-incompetent form.
Polymerization-Incompetent Umod Is Increased in 
Pregnant SHRSP
N-deglycosylation of Umod using PNGase F confirmed the 
presence of 2 forms of Umod: a longer polypeptide (≈59 
kDa) and a shorter polypeptide (≈54 kDa; Figure 4B). The 
presence of the 59-kDa polypeptide of Umod was increased 
in the urine of SHRSP compared with WKY at all time 
points (Figure 4B). The polymerization assay identified 
Umod both in the supernatant (polymerization incompe-
tent) and pellet (polymerization competent) in both strains 
(Figure 4C). In nonpregnant rats, both polymerization-
competent and polymerization-incompetent Umod were 
detected in WKY and SHRSP at similar levels (Figure 4C). 
On pregnancy, the polymerization-incompetent Umod 
decreased in a gestation-dependent manner in the WKY 
(Figure 4C). In contrast, the polymerization-incompetent 
form of Umod increased over pregnancy in the SHRSP 
(Figure 4B and 4C).
Figure 1. Schematic flowchart representing peptidomics data analysis and identification of peptide markers. The counterplot at the top 
represents the peptide mass fingerprint pattern of Wistar–Kyoto (WKY; n=7) and stroke-prone spontaneously hypertensive rat (SHRSP); 
n=7) at prepregnancy (nonpregnant [NP]) and gestational days (GDs) 12 and 18 observed in capillary electrophoresis–mass spectrometry. 
On the plot, X-axis represents the CE-migration time, Y-axis mass:charge ratio, and Z-axis the peptide signal intensity. Various 
comparisons were made between strains and GDs. The numbers above the arrow represent the number of peptide identified during the 
comparison with P<0.05. The strain- and pregnancy-specific peptide markers were not used to for analysis. The disease-specific peptide 
markers were analyzed for pattern of significance, that is, at P<0.05 whether the peptide was significant at a given GD. Star marked 
pattern of significance represents peptides that were significant at all GD or GDs 12–18 and were further used for analysis.
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Nifedipine-Treated Pregnant SHRSP Showed Only 
Polymerization-Competent Umod
To determine whether the presence of hypertension altered 
the peptidomic profile of Umod in the SHRSP, urine samples 
were analyzed from SHRSP treated with nifedipine from 7 
weeks of age (Figure S1). Urine samples from pregnant nife-
dipine-treated SHRSP showed that nifedipine-treated rats had 
only a single band of N-deglycosylated Umod in Western blot 
(Figure 4B). In the polymerization assay from these samples, 
Umod was present only as the polymerization-competent 
form, whereas the polymerization-incompetent form was 
undetectable at both GD12 and GD18 (Figure 4C).
Protease Activity on Polymerization-Incompetent 
Umod
When analyzing peptides of Umod, it is important to under-
stand how these were derived from the full-length protein 
through the action of various proteases. Proteasix software21 
was used to predict the proteases that might be responsible 
for cleaving the polymerization-incompetent Umod at the 
C-terminal in silico. Most of these predicted proteases were 
classified as either a serine protease or a metalloprotease. 
Meprin A subunit α, a metallopeptidase was predicted with 
medium confidence, whereas other proteases such as gran-
zyme A, cathepsin G, matrix metalloproteases 3 and 12, plas-
minogen, and neutrophil elastase were predicted with lower 
confidence (Figure 4D; Table S3).
Discussion
Interrogation of the urinary peptidome over gestation in 
WKY and SHRSP showed that there are strain-dependent and 
pregnancy-dependent alterations. To identify relevant pep-
tides, we focused on 123 peptides that were found to be dif-
ferentially expressed between WKY and SHRSP at all time 
points (nonpregnant, GD12, and GD18) or at GD12 and GD18 
only. These 123 peptides were principally composed of colla-
gen α chains, serum albumin, prothrombin, actin, serpin A3K, 
proepidermal growth factor, and Umod. In comparison, in 
urinary peptidomic screens of women with preeclampsia, the 
most common constituents are albumin and tubular proteins 
that are thought to reflect renal tubule damage.24 However, a 
characteristic and specific signature for human preeclampsia 
are yet to be determined despite many studies.24 The nonbiased 
peptidome screening of urine collected prepregnancy, GD12 
and GD18 led to the identification of Umod peptides that were 
increased in a pregnancy-dependent manner in SHRSP rela-
tive to WKY. Further investigation of these peptides revealed 
that they were all derived from the polymerization-inhibitory 
region of Umod. In keeping with this finding, Umod polym-
erization was altered between WKY and SHRSP, specifically 
the polymerization-incompetent form of Umod was increased 
in pregnant SHRSP. Our data are the first to introduce a role of 
polymerization of Umod in hypertensive pregnancy.
Umod has been extensively studied in association with 
cardiovascular conditions in humans. Genome-wide associa-
tion studies have identified UMOD variants associated with 
renal function and hypertension.25 However, the role of Umod 
in hypertensive pregnancy has not yet been subject to detailed 
study. All 7 of the urinary Umod peptides detected in the pres-
ent screen were increased in a pregnancy-dependent manner 
in the SHRSP relative to the WKY. The SHRSP pregnancy-
dependent increase in Umod was validated by increased Umod 
Figure 2. Urinary Umod peptides are increased in the stroke-prone spontaneously hypertensive rat (SHRSP) relative to Wistar–Kyoto 
(WKY) in a pregnancy-dependent manner. Seven peptides detected in the urinary peptidome were derived from Umod protein (A). Of 
these peptides, they were all increased in a pregnancy-specific manner in SHRSP (n=7) relative to WKY (n=7) at gestational days (GDs) 
12, GD18, or GD12 and GD18. Taking into account the sum of all of the 7 peptides (B) showed that Umod peptides were increased in a 
pregnancy-specific manner at GD12 and GD18 in SHRSP relative to WKY (*P<0.05, **P<0.01 vs WKY analyzed by Wilcoxon rank test).
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gene and protein expression in kidney tissue at GD18. Umod 
protein expression in urine of WKY rats showed decrease over 
pregnancy (nonsignificant), whereas in SHRSP, its expression 
is increased significantly. One limitation of our model is that 
urinary Umod increases with gestation in human pregnancy, 
whereas there is a decrease in urinary Umod in the WKY. 
Umod is the most abundant protein in the urine, secreted by 
the epithelial cells lining the thick ascending limb of the loop 
of Henle in the kidney. The full-length Umod in endoplasmic 
reticulum gets N-glycosylated and glypiated at its C terminus 
and further modified in Golgi apparatus. The mature Umod 
with glycosylphosphatidylinositol modification (at S615) is 
anchored to the apical membrane of thick ascending limb fac-
ing the tubular lumen. The secreted form of Umod is released 
by the proteolytic activity of hepsin, a type II transmembrane 
serine protease (at R591 in rat evidenced by sequence similar-
ity).26 Polymerization of secreted Umod helps in the formation 
of a filamentous gel-like structure that acts a physical barrier 
for ion transport to maintain countercurrent gradients in the 
interstitium.27,28 Cleavage by hepsin releases the polymeriza-
tion-inhibitory motif (extracellular hydrophobic patch) that 
prevents premature intracellular protein assembly.26,29
Urinary peptidomics presented in this article indicated 
that the Umod peptide 592-SGNFIDQTRVLNLGPITR-609 
and its smaller fragments were released into the urine. We 
found these peptides upregulated in pregnant SHRSP rats, 
as well as in urine samples from 2 independent cohorts of 
women with preeclampsia in other work.22,23 This sequence 
592 to 609 consisted of the polymerization-inhibitory motif 
(601–610), downstream of the hepsin cleavage site (R591) 
and upstream of glycosylphosphatidylinositol anchoring. 
This led to the question as to whether these peptide fragments 
were released from the membrane after hepsin cleavage or 
were these fragments cleaved from a longer form of Umod 
polypeptide. To address this, N-deglycosylation of Umod was 
performed where 2 polypeptides were identified. The polym-
erization assay confirmed the existence of 2 forms of Umod, 
the longer polymerization-incompetent and shorter polymer-
ization-competent polypeptides.
The longer polymerization-incompetent Umod was 
observed in nonpregnant WKY and SHRSP. This indicates that 
the release of a longer polypeptide is a common phenomenon 
in these strains. However, during pregnancy, the release of the 
longer polypeptide is higher in SHRSP than in WKY. This 
indicates that there is less Umod polymerization in SHRSP. 
We hypothesize that the longer polypeptides are later cleaved 
by other as yet unidentified proteases to form the shorter poly-
peptide, which releases the peptides that were observed in the 
Figure 3. Increase in Umod in stroke-prone spontaneously hypertensive rat (SHRSP) validated in urine and kidney tissue. A, Purified 
Umod from the urine of Wistar–Kyoto (WKY; n=7) and SHRSP (n=7) was run on 10% NuPAGE gel and blotted onto a single polyvinylidene 
fluoride membrane. Umod showed an increase in SHRSP in pregnancy-dependent manner at gestational days (GDs) 12 and 18. B, Gene 
expression of Umod was measured in kidney tissue from nonpregnant and pregnant (GD18) WKY and SHRSP (n=5). Umod expression 
was increased in kidney tissue from SHRSP at both NP (P=n.s.) and GD18 time points (P<0.001). C, Umod protein was measured from 
kidney tissue extract of pregnant (GD18) SHRSP (n=4) and WKY (n=4). Pregnant SHRSP showed increased Umod expression in kidney 
tissue (**P<0.01, ***P<0.001 vs WKY analyzed by 1-way ANOVA, 2-way ANOVA, and t test).
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urinary peptidome. Furthermore, the activity of the predicted 
proteases should be increased in SHRSP during pregnancy 
corresponding to the higher levels of the 7 protein fragments 
of Umod observed in the urinary peptidome data. The pre-
liminary prediction data generated using Proteasix identified 
many candidate proteases for further study.
Figure 4. A, Schematic representation of rat Umod structure containing an epidermal growth factor–like domain (orange box I, II, 
and III), the Zona Pellucida (ZP) domain, internal and external hydrophobic patches (IHP and EHP, respectively), hepsin cleavage site 
and glycosylphosphatidylinositol (GPI) anchoring site. The zoomed-in sequence represents the C-terminal region identified in mass 
spectrometry rat data (pink) and previous human studies on preeclampsia (blue). B, Deglycosylation of Umod identified 2 bands in 
untreated WKY (pool of n=7) and stroke-prone spontaneously hypertensive rat (SHRSP; pool of n=7) at all gestational day (GD), and only 
single band in nifedipine-treated SHRSP (pool of 3) at GD12 and GD18. C, In the polymerization assay, the pellet fraction (P) represents 
the polymerization-competent and supernatant (S) the polymerization-incompetent Umod. Polymerization assay showed polymerization-
incompetent Umod in the supernatant (S) of untreated WKY (pool of n=7) and SHRSP (pool of n=7) at all GDs, whereas no Umod bands 
were observed in nifedipine-treated SHRSP (pool of 3). Polymerization-competent Umod in the pellet (P) was observed in untreated WKY 
and SHRSP, as well as in nifedipine-treated SHRSP. D, Proteasix software predicted few serine proteases and metalloproteases that 
might cleave the C-terminal of Umod, which resulted in the peptides observed in urine. CTSG indicates cathepsin G; ELANE, neutrophil 
elastase; GZMA, granzyme A; MEP, Meprin A subunit α; MMP, matrix metalloprotease; NP, nonpregnant; and PLG, plasminogen.
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The correlation between hypertension during pregnancy 
and release of Umod peptides warrants further investigation. 
We made an attempt to explore the effect of blood pressure 
on Umod polymerization when pregnant SHRSP were treated 
with the antihypertensive drug, nifedipine, from 7 weeks of 
age. It was found that nifedipine-treated rats expressed only 
the polymerization-competent Umod. Nifedipine principally 
acts as a calcium channel blocker and is known to reduce 
urinary protein excretion rate in patients with renal disease30 
and decrease urinary calcium excretion in women with pre-
eclampsia.29 In this study, nifedipine treatment significantly 
lowered the blood pressure of the pregnant SHRSP. The 
effect of nifedipine indicates 2 possible mechanisms that 
drive Umod polymerization. First, the role of calcium in 
regulating the polymer formation, and second, the existence 
of an indirect unknown mechanism that modulates hyperten-
sion and polymer formation. Umod is known to have 3 epi-
dermal growth factor–like domains at the N terminus where 
2 of these domains, epidermal growth factor–like 2 (D67-
I108) and epidermal growth factor–like 3 (D109-E150), are 
calcium-binding domains that have implications in protein–
protein interaction. Umod is also known to play a protective 
role against calcium crystal formation.31 The predicted pro-
teases such as granzyme A, matrix metalloproteinase matrix 
metalloproteases 3 and 12, metalloendopeptidase, neutrophil 
elastase, plasmin are all dependent on calcium for their activ-
ity, expression, or structure.32–36 These proteases were derived 
from in silico analysis in the current study. Future work on 
determining the expression of each of these proteases, and 
their role in Umod cleavage should be undertaken in future 
studies.
Perspectives
SHRSP exhibit strain-dependent and pregnancy-dependent alter-
ations in their urinary peptidome relative to the WKY. The pro-
tein Umod, which has already been shown to have an important 
role in systemic hypertension, has been highlighted in this study 
as a potential protein of interest in hypertensive pregnancy, espe-
cially in terms of its polymer formation function. At this stage, it 
is not clear whether Umod polymerization is a counter-regulatory 
mechanism or secondary to the development of hypertension. 
These findings warrant future work to reciprocate these findings 
in human samples and the molecular dissection of Umod polym-
erization during healthy and hypertensive pregnancy.
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What Is New?
•	This is the first study to identify a role for uromodulin polymerization in 
hypertensive pregnancy.
•	We identified elevated levels of uromodulin peptides in the urine of preg-
nant stroke-prone spontaneously hypertensive rat relative to the control 
Wistar–Kyoto rat.
•	The pregnant stroke-prone spontaneously hypertensive rat shows el-
evated levels of polymerization-competent uromodulin, which is signifi-
cantly reduced with antihypertensive treatment.
What Is Relevant?
•	Hypertensive pregnancy is the most common pregnancy complication 
encountered and contributes substantially to maternal and fetal morbid-
ity and mortality.
•	Uromodulin is extensively studied in relation to systemic arterial hyper-
tension; here, we report its role in hypertensive pregnancy.
Summary
Pregnant stroke-prone spontaneously hypertensive rat exhibit an al-
tered urinary peptidome relative to Wistar–Kyoto rats. Uromodulin is 
associated with hypertension and other cardiovascular disorders in 
humans and preclinical models. Elevated levels of polymerization-in-
competent uromodulin were seen in pregnant stroke-prone spontane-
ously hypertensive rat, which were not detectable in nifedipine-treat-
ed pregnant stroke-prone spontaneously hypertensive rat. The role 
and mechanism of polymerization of uromodulin in hypertension and 
hypertensive pregnancy warrants further study in human subjects.
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Table S1: 123 urinary peptides altered between WKY and SHRSP at all time points (NP, GD12 and GD18) or GD12 & GD18 only 
PeptideID Mass [Da] 
Migration 
time [Min] 
Log2 peptide intensity Fold change (WKY/ SHRSP) 
WKY 
NP 
SHRSP 
NP 
WKY 
GD12 
SHRSP 
GD12 
WKY 
GD18 
SHRSP 
GD18 
NP GD12 GD18 
929 857.4815 28.15 5.93 6.28 6.35 7.03 5.97 7.12 0.94 0.90 0.84 
1054 862.4315 22.67 6.57 8.10 8.11 6.86 6.86 6.36 0.81 1.18 1.08 
1304 874.4576 34.49 7.49 6.14 7.73 5.75 6.64 3.95 1.22 1.34 1.68 
4119 1009.498 37.80 12.33 13.33 12.23 12.91 11.82 13.09 0.92 0.95 0.90 
4706 1046.479 47.56 5.75 6.67 5.57 7.32 6.13 4.75 0.86 0.76 1.29 
5098 1073.363 46.52 13.04 13.67 13.11 13.83 13.28 14.25 0.95 0.95 0.93 
5254 1083.533 36.50 11.96 11.35 12.24 11.21 12.08 11.42 1.05 1.09 1.06 
5474 1099.53 36.52 8.98 7.83 9.31 7.72 9.86 8.23 1.15 1.21 1.20 
5497 1100.587 28.83 7.31 5.11 8.58 7.67 8.52 6.09 1.43 1.12 1.40 
5661 1111.608 30.47 7.52 4.06 8.29 5.98 7.90 5.15 1.85 1.39 1.53 
6367 1155.575 29.05 6.57 4.10 7.14 3.41 8.39 4.48 1.60 2.09 1.87 
6546 1167.54 47.90 4.49 5.59 4.63 3.92 5.08 4.30 0.80 1.18 1.18 
7006 1196.367 47.02 12.07 12.79 12.42 13.09 12.91 13.48 0.94 0.95 0.96 
7982 1255.65 26.25 6.73 4.55 7.88 3.90 6.75 5.44 1.48 2.02 1.24 
8591 1295.622 29.62 8.05 3.67 8.18 3.00 9.73 4.23 2.19 2.73 2.30 
9325 1341.649 38.48 6.65 5.63 6.62 5.30 7.52 5.21 1.18 1.25 1.44 
10270 1407.682 48.28 7.91 9.23 8.50 9.14 8.91 6.45 0.86 0.93 1.38 
10772 1444.684 40.04 4.60 5.84 4.28 3.39 7.37 4.59 0.79 1.26 1.61 
11141 1471.739 39.49 4.27 4.30 4.99 4.22 5.34 4.74 0.99 1.18 1.13 
12407 1564.769 39.41 7.19 5.89 8.34 6.64 8.90 5.66 1.22 1.26 1.57 
12582 1579.76 26.34 8.60 7.18 10.10 8.95 9.86 6.87 1.20 1.13 1.44 
12628 1584.553 47.97 10.32 12.13 11.42 12.12 11.48 12.24 0.85 0.94 0.94 
12969 1611.795 40.17 5.59 7.54 5.92 6.83 5.78 7.19 0.74 0.87 0.80 
13270 1635.838 33.09 6.11 4.45 6.30 3.66 7.01 4.56 1.37 1.72 1.53 
13543 1659.818 39.66 8.96 6.90 9.43 6.79 9.41 5.46 1.30 1.39 1.72 
13580 1663.806 40.59 8.70 5.54 9.39 4.19 8.92 4.80 1.57 2.24 1.86 
13742 1679.814 40.76 7.82 6.23 8.45 5.75 7.40 5.22 1.25 1.47 1.42 
14788 1780.881 28.09 6.98 4.44 9.02 2.89 9.26 4.33 1.57 3.12 2.14 
14896 1790.854 33.26 6.62 4.42 8.29 5.42 8.28 4.66 1.50 1.53 1.78 
  
PeptideID Mass [Da] 
Migration 
time [Min] 
Log2 peptide intensity Fold change (WKY/ SHRSP) 
WKY 
NP 
SHRSP 
NP 
WKY 
GD12 
SHRSP 
GD12 
WKY 
GD18 
SHRSP 
GD18 
NP GD12 GD18 
15819 1885.854 28.11 9.79 4.57 10.90 3.50 11.42 4.68 2.14 3.12 2.44 
100383 1139.544 28.69 9.92 6.65 10.46 7.06 10.89 6.37 1.49 1.48 1.71 
100433 1173.604 26.22 6.30 4.47 7.69 3.67 6.06 4.87 1.41 2.10 1.24 
100744 1417.721 26.35 5.87 4.27 7.21 4.15 6.42 4.65 1.37 1.74 1.38 
100773 1433.684 32.66 7.07 5.52 7.79 6.11 7.93 6.28 1.28 1.28 1.26 
100916 1532.692 39.51 6.33 8.34 8.62 9.19 7.00 9.06 0.76 0.94 0.77 
100954 1554.759 26.62 6.33 4.60 7.18 3.57 6.80 4.57 1.38 2.01 1.49 
100964 1561.754 28.12 7.59 4.19 8.80 3.89 8.20 4.91 1.81 2.26 1.67 
101001 1584.787 27.29 7.10 4.52 8.12 3.52 8.32 4.83 1.57 2.31 1.72 
101201 1713.872 28.25 7.19 4.43 8.82 3.54 9.03 4.84 1.62 2.49 1.87 
101224 1726.832 28.14 5.34 4.55 5.81 3.76 6.37 4.69 1.17 1.54 1.36 
101391 1832.94 33.34 6.33 4.54 6.28 3.54 7.78 4.94 1.39 1.77 1.57 
101392 1833.646 48.36 5.17 6.55 4.94 6.58 6.78 4.81 0.79 0.75 1.41 
101695 2013.958 25.17 8.05 4.63 8.93 3.74 9.39 5.05 1.74 2.39 1.86 
102001 2196.056 25.43 7.54 4.18 9.66 3.76 9.26 4.61 1.80 2.57 2.01 
102056 2239.077 26.87 8.01 4.65 9.33 3.52 8.34 5.06 1.72 2.65 1.65 
106356 1418.602 48.47 7.81 4.70 7.40 3.86 8.73 5.14 1.66 1.92 1.70 
880 855.4258 35.91 9.61 10.94 9.42 10.64 8.86 11.32 0.88 0.88 0.78 
1512 883.4193 35.35 7.59 8.27 7.77 6.69 8.43 6.66 0.92 1.16 1.27 
1615 888.4502 34.67 7.05 6.27 8.22 5.97 7.04 4.86 1.13 1.38 1.45 
2684 931.5043 27.26 7.97 7.67 7.49 9.31 7.82 8.83 1.04 0.80 0.89 
2981 947.4504 34.20 7.66 7.31 7.23 5.09 7.51 5.79 1.05 1.42 1.30 
3258 960.5006 29.69 5.54 6.03 7.14 5.88 5.93 4.99 0.92 1.21 1.19 
3668 982.5227 36.14 10.42 10.22 10.41 9.58 10.30 8.68 1.02 1.09 1.19 
3784 989.4635 47.52 6.51 6.42 6.74 7.99 7.02 5.54 1.01 0.84 1.27 
3791 989.5253 28.87 8.40 9.05 7.80 9.24 6.99 8.98 0.93 0.84 0.78 
3930 998.4752 34.70 10.08 9.68 9.56 8.17 9.43 6.41 1.04 1.17 1.47 
4042 1004.478 47.47 7.44 8.21 7.72 8.92 8.85 6.97 0.91 0.87 1.27 
4680 1044.505 36.33 6.11 7.63 6.18 5.59 6.53 5.53 0.80 1.11 1.18 
4824 1055.523 36.37 9.66 9.55 9.44 8.94 9.49 8.91 1.01 1.06 1.06 
5014 1068.567 29.18 5.30 4.67 5.62 3.91 5.66 4.84 1.14 1.44 1.17 
  
PeptideID Mass [Da] 
Migration 
time [Min] 
Log2 peptide intensity Fold change (WKY/ SHRSP) 
WKY 
NP 
SHRSP 
NP 
WKY 
GD12 
SHRSP 
GD12 
WKY 
GD18 
SHRSP 
GD18 
NP GD12 GD18 
5114 1073.515 36.41 6.52 5.76 5.98 3.96 6.25 5.09 1.13 1.51 1.23 
5789 1119.531 48.01 4.82 5.38 4.67 5.91 6.64 5.91 0.90 0.79 1.12 
6058 1134.515 47.95 6.16 4.69 4.99 5.56 7.18 5.16 1.31 0.90 1.39 
6252 1148.544 48.13 4.93 4.99 4.94 5.90 6.36 5.00 0.99 0.84 1.27 
6545 1167.564 29.66 8.30 5.88 5.88 7.50 5.67 9.18 1.41 0.78 0.62 
7181 1206.626 25.61 6.64 5.38 6.25 7.93 7.04 5.14 1.23 0.79 1.37 
7302 1214.566 37.03 11.12 11.34 11.69 11.14 11.60 12.04 0.98 1.05 0.96 
7534 1227.606 37.47 10.57 10.37 10.26 9.45 10.65 9.95 1.02 1.09 1.07 
8404 1283.405 47.36 6.44 6.77 7.21 3.99 8.16 6.39 0.95 1.81 1.28 
8590 1295.61 37.80 5.85 5.95 6.53 4.29 7.54 5.62 0.98 1.52 1.34 
8661 1300.715 39.78 5.99 4.46 7.22 3.86 8.35 4.88 1.34 1.87 1.71 
9006 1321.704 32.99 6.65 6.20 6.63 5.18 7.11 5.92 1.07 1.28 1.20 
9090 1324.681 29.94 7.57 7.03 9.26 7.61 9.05 6.34 1.08 1.22 1.43 
9131 1326.631 39.17 8.23 9.06 8.20 5.14 7.11 5.30 0.91 1.60 1.34 
9601 1358.66 32.35 7.02 7.36 5.34 6.53 6.96 5.43 0.95 0.82 1.28 
9863 1378.668 39.11 10.44 10.55 10.86 10.08 10.22 9.15 0.99 1.08 1.12 
9871 1378.731 31.31 6.94 6.50 8.40 7.60 8.35 6.65 1.07 1.11 1.26 
10013 1388.717 39.15 9.66 9.21 10.47 9.54 9.82 8.04 1.05 1.10 1.22 
10393 1415.706 39.41 5.71 5.70 5.80 6.85 6.18 5.72 1.00 0.85 1.08 
10625 1434.691 48.95 4.71 7.65 6.15 8.04 7.28 7.07 0.62 0.76 1.03 
11179 1474.77 26.54 4.98 4.51 5.79 4.18 5.51 4.64 1.10 1.38 1.19 
11487 1497.745 31.62 4.91 4.49 5.23 3.61 5.03 4.42 1.09 1.45 1.14 
11667 1511.678 39.29 5.95 6.83 6.13 5.35 6.38 5.45 0.87 1.14 1.17 
11737 1515.825 32.86 4.71 6.21 6.72 5.36 4.86 5.78 0.76 1.25 0.84 
12757 1594.92 33.72 6.04 5.80 4.70 6.45 5.86 8.83 1.04 0.73 0.66 
12958 1610.734 38.89 6.83 6.16 8.06 4.90 7.45 4.53 1.11 1.65 1.65 
13079 1620.735 32.13 5.06 4.48 5.99 3.96 6.87 4.57 1.13 1.51 1.50 
13290 1636.792 40.73 10.05 10.03 10.51 9.77 9.67 8.59 1.00 1.08 1.13 
13458 1650.839 33.29 5.19 4.89 6.68 4.79 5.98 4.59 1.06 1.39 1.30 
13670 1671.9 28.18 7.11 6.31 8.28 6.70 6.81 4.66 1.13 1.24 1.46 
13740 1679.77 32.30 9.18 9.20 9.07 8.01 9.78 8.75 1.00 1.13 1.12 
  
PeptideID Mass [Da] 
Migration 
time [Min] 
Log2 peptide intensity Fold change (WKY/ SHRSP) 
WKY 
NP 
SHRSP 
NP 
WKY 
GD12 
SHRSP 
GD12 
WKY 
GD18 
SHRSP 
GD18 
NP GD12 GD18 
13819 1687.84 41.42 5.26 4.85 5.32 4.24 5.58 4.59 1.08 1.25 1.22 
14020 1706.866 41.37 7.12 8.04 8.11 7.12 7.37 5.42 0.89 1.14 1.36 
14404 1743.872 33.58 6.88 6.17 7.60 6.29 6.51 5.11 1.11 1.21 1.27 
15228 1825.811 40.93 6.65 7.42 7.23 6.53 6.96 5.55 0.90 1.11 1.25 
16047 1905.941 34.11 8.35 7.80 9.16 7.25 6.44 5.27 1.07 1.26 1.22 
16054 1906.927 42.64 8.95 9.25 8.80 7.90 8.12 5.89 0.97 1.11 1.38 
16851 1992.943 42.36 8.77 9.29 9.21 8.36 8.20 7.30 0.94 1.10 1.12 
16914 2000.106 35.84 8.97 9.41 7.33 9.83 7.61 11.52 0.95 0.75 0.66 
17594 2072.013 40.74 6.32 6.90 7.02 5.83 6.98 5.04 0.92 1.20 1.38 
17878 2099.082 42.32 6.14 7.02 6.11 4.23 5.76 5.15 0.88 1.45 1.12 
20566 2420.078 44.61 7.04 7.68 7.16 5.77 6.39 4.77 0.92 1.24 1.34 
21602 2566.11 44.92 5.86 6.61 6.42 5.13 5.45 4.77 0.89 1.25 1.14 
29610 3981.973 38.00 5.17 4.45 7.19 4.64 6.16 4.40 1.16 1.55 1.40 
33289 5452.868 24.75 11.77 11.77 10.45 12.70 12.27 8.41 1.00 0.82 1.46 
100000 800.3959 33.34 8.16 7.23 7.97 6.08 8.15 6.32 1.13 1.31 1.29 
100026 828.4175 33.50 6.76 7.59 7.67 6.31 7.10 5.33 0.89 1.22 1.33 
100111 902.4517 29.35 6.53 5.56 5.89 4.96 5.69 4.71 1.18 1.19 1.21 
100343 1095.353 47.05 7.70 5.81 5.62 8.58 7.54 5.58 1.32 0.66 1.35 
100542 1253.576 37.28 6.04 5.74 6.71 3.38 7.61 5.45 1.05 1.98 1.40 
100572 1274.494 47.99 5.81 5.64 7.80 5.10 7.87 5.09 1.03 1.53 1.55 
100806 1456.767 27.87 4.88 4.34 6.49 3.77 6.23 4.55 1.12 1.72 1.37 
100913 1529.64 29.08 5.58 5.96 7.43 9.05 7.38 8.35 0.94 0.82 0.88 
101148 1675.841 41.45 5.90 5.66 6.60 3.80 6.44 4.69 1.04 1.74 1.37 
101272 1753.899 50.19 5.49 5.94 5.60 3.57 7.09 4.92 0.92 1.57 1.44 
101403 1837.903 28.25 5.91 4.33 8.18 3.73 8.58 4.47 1.37 2.19 1.92 
101420 1849.971 29.18 5.92 4.96 7.31 5.51 5.86 4.90 1.19 1.33 1.20 
101782 2060.054 42.88 5.29 6.96 6.97 4.05 6.43 4.22 0.76 1.72 1.52 
101946 2165.127 30.74 5.07 4.46 5.74 3.55 5.90 5.22 1.14 1.62 1.13 
102676 3411.458 28.83 5.13 5.84 5.77 5.83 5.64 4.81 0.88 0.99 1.17 
102804 4113.821 47.13 4.65 4.25 6.77 3.70 4.98 4.50 1.09 1.83 1.11 
102868 4816.223 32.08 5.01 4.66 5.19 3.56 5.06 4.41 1.08 1.46 1.15 
  
PeptideID Mass [Da] 
Migration 
time [Min] 
Log2 peptide intensity Fold change (WKY/ SHRSP) 
WKY 
NP 
SHRSP 
NP 
WKY 
GD12 
SHRSP 
GD12 
WKY 
GD18 
SHRSP 
GD18 
NP GD12 GD18 
107005 1694.835 33.02 5.52 4.25 6.85 4.44 6.47 4.44 1.30 1.54 1.46 
 
  
Table S2: Sequenced peptides list 
PeptideID 
Mass 
[Da] 
Sequence Protein name 
Theoretical 
Mass 
Start 
AA 
Stop 
AA 
Rat.Protein 
Accessions 
12757 1594.92 IDQTRVLNLGPITR Uromodulin 1594.91549 596 609 P27590 
16914 2000.106 SGNFIDQTRVLNLGPITR Uromodulin 2000.080323 592 609 P27590 
9131 1326.631 TVDETYVPKEF Serum albumin  1326.634348 516 526 P02770 
11179 1474.77 SVIHEDVYEEKK RCG32337, isoform CRA_a 1474.730374 47 58 D3ZJA4 
14788 1780.881 DKTEKELLDSYIDGR Prothrombin  1780.884309 345 359 P18292 
3668 982.5227 VPSYPGPpGP Protein Col19a1 982.569898 76 84 D3ZCQ0 
8590 1295.61 DPVESKIYFAQ Pro-epidermal growth factor  1295.639768 522 532 P07522 
11667 1511.678 AGPpGPpGpPGSIGHpG 
procollagen, type IX, alpha 3 
(predicted), isoform CRA_a 
1511.700471 555 571 D3ZX71 
12958 1610.734 LAQLmANEWPHSQA 
NACHT, leucine rich repeat and 
PYD containing 5 
1610.751105 69 82 D3ZDM5 
9006 1321.704 DGILGRDTLPHE 
Contrapsin-like protease inhibitor 
1  
1321.662629 21 32 P05545 
11141 1471.739 ALYQAEAFVADFK 
Contrapsin-like protease inhibitor 
1 
1471.734731 155 167 P05545 
11487 1497.745 GPPGpPGDPGKPGAPGK Collagen alpha-1(IX) chain 1497.757592 68 84 F1LQ93 
13742 1679.814 GMpGSpGGPGNDGKPGPpG Collagen alpha-1(III) chain 1679.720948 536 554 P13941 
14896 1790.854 GESGRpGPpGPSGPRGQpG Collagen alpha-1(III) chain 1790.829588 557 575 P13941 
16851 1992.943 QGIpGTSGPpGENGKpGEpGP Collagen alpha-1(III) chain 1992.902478 640 660 P13941 
4706 1046.479 GppGPpGPpGPG Collagen alpha-1(II) chain 1046.466889 1139 1150 P05539 
9863 1378.668 ApGEDGRpGPpGPQ Collagen alpha-1(II) chain 1378.611322 512 525 P05539 
10625 1434.691 GPpGPpGPpGPPSGGY Collagen alpha-1(I) chain  1434.641559 1170 1185 P02454 
3784 989.4635 GppGPpGPpGP Collagen alpha-1(I) chain  989.445425 131 141 P02454 
4042 1004.478 GPpGPpGPPSGG Collagen alpha-1(I) chain  1004.456324 1173 1184 P02454 
  
PeptideID 
Mass 
[Da] 
Sequence Protein name 
Theoretical 
Mass 
Start 
AA 
Stop 
AA 
Rat.Protein 
Accessions 
4119 1009.498 GRVGPpGPSGN Collagen alpha-1(I) chain  1009.494075 870 880 P02454 
6546 1167.54 GPpGPpGPPSGGY Collagen alpha-1(I) chain  1167.519653 1173 1185 P02454 
4680 1044.505 ApGFpGARGPS Collagen alpha-1(I) chain 1044.498815 397 407 P02454 
5254 1083.533 GVVGLpGQRGE Collagen alpha-1(I) chain 1083.483267 828 839 P02454 
5789 1119.531 GPpGPTGPTGPpG Collagen alpha-1(I) chain 1119.519653 321 333 P02454 
6252 1148.544 GLpGPpGApGPQG Collagen alpha-1(I) chain 1148.546202 177 189 P02454 
9090 1324.681 GLpGpKGDRGDAGP Collagen alpha-1(I) chain 1324.637142 726 739 P02454 
10013 1388.717 RpGEVGPpGPpGPAG Collagen alpha-1(I) chain 1388.668442 907 921 P02454 
11737 1515.825 GPpGPpGPVGKEGGKGP Collagen alpha-1(I) chain 1515.768157 882 898 P02454 
13079 1620.735 DGVAGPKGPAGERGSpGP Collagen alpha-1(I) chain 1620.785598 488 505 P02454 
13290 1636.792 GSpGSpGPDGKTGPpGPAG Collagen alpha-1(I) chain 1636.732893 531 549 P02454 
13670 1671.9 PpGPpGPVGKEGGKGPRG Collagen alpha-1(I) chain 1671.869268 882 899 P02454 
14020 1706.866 TGPIGPpGPAGApGDKGET Collagen alpha-1(I) chain 1706.811144 755 773 P02455 
13543 1659.818 GAPGAKGNVGppGEPGPpG Alpha 4 type V collagen 1659.785263 620 638 P68136 
4824 1055.523 NELRVAPEE Actin, alpha skeletal muscle 1055.524738 94 102 P68136 
 
  
Table S3: Proteasix prediction 
 
Peptide
_ID
Termin
us
Start
_AA
Stop
_AA
Peptide_sequence Cleavage_ 
site_ 
sequence
Protease Status MEROPS-
based 
probability
99th_ 
percentil
e
Threshold
_  for_High
Threshold_  
for_Mediu
m
Confidence Score
11288 C 597 609 DQTRVLNLGPITR PITRQGVQ GZMA (P12544) Predicted -19.74654075 -20.3476 79.293888 91.4181042 Low 97.04595
12110 C 593 606 GNFIDQTRVLNLGP NLGPITRQ MMP3 (P08254) Predicted -20.9298539 -20.967 82.112386 94.6537705 Low 99.82298
3188 C 596 603 IDQTRVLN RVLNLGPI MEP1A (Q16819) Predicted -19.90823817 -21.2123 84.591496 94.7405127 Medium 93.85246
3188 C 596 603 IDQTRVLN RVLNLGPI CTSG (P08311) Predicted -20.95645506 -21.4532 80.981024 92.11372 Low 97.68461
3188 C 596 603 IDQTRVLN RVLNLGPI MMP12 (P39900) Predicted -20.89684797 -20.9588 76.103689 92.2565783 Low 99.70427
12757 C 596 609 IDQTRVLNLGPITR PITRQGVQ GZMA (P12544) Predicted -19.74654075 -20.3476 79.293888 91.4181042 Low 97.04595
9646 C 592 603 SGNFIDQTRVLN RVLNLGPI MEP1A (Q16819) Predicted -19.90823817 -21.2123 84.591496 94.7405127 Medium 93.85246
9646 N 592 603 SGNFIDQTRVLN TRYRSGNF PLG (P00747) Predicted -19.86839738 -20.0324 91.672952 94.6937508 Low 99.18116
9646 C 592 603 SGNFIDQTRVLN RVLNLGPI CTSG (P08311) Predicted -20.95645506 -21.4532 80.981024 92.11372 Low 97.68461
9646 C 592 603 SGNFIDQTRVLN RVLNLGPI MMP12 (P39900) Predicted -20.89684797 -20.9588 76.103689 92.2565783 Low 99.70427
14390 C 592 607 SGNFIDQTRVLNLGPI LGPITRQG ELANE (P08246) Predicted -20.12871325 -21.2425 86.361487 94.1113 Low 94.75676
14390 N 592 607 SGNFIDQTRVLNLGPI TRYRSGNF PLG (P00747) Predicted -19.86839738 -20.0324 91.672952 94.6937508 Low 99.18116
16914 C 592 609 SGNFIDQTRVLNLGPITR PITRQGVQ GZMA (P12544) Predicted -19.74654075 -20.3476 79.293888 91.4181042 Low 97.04595
16914 N 592 609 SGNFIDQTRVLNLGPITR TRYRSGNF PLG (P00747) Predicted -19.86839738 -20.0324 91.672952 94.6937508 Low 99.18116
  
 
Supplementary figure S1: Nifedipine significantly inhibits blood pressure 
elevation in the SHRSP. Systolic (SBP) (A) and diastolic (DBP) (B) blood 
pressure was monitored in untreated WKY, untreated SHRSP and nifedipine 
treated SHRSP (n=6) using radiotelemetry before day 0 and during pregnancy 
(gestational day 0 – day 21). SHRSP had significantly increased blood 
pressure compared to WKY (* p<0.05). Nifedipine treatment significantly 
reduced SHRSP blood pressure (## p<0.01 vs. SHRSP). Data analysed by 
comparing area under the curve values using one way ANOVA and Tukey’s 
post-hoc test. 
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